Baudax Bio, Inc.
Other OTCTotal Valuation
Baudax Bio, Inc. carries a market capitalization of 4,359.00, placing it among publicly traded companies globally. Its enterprise value stands at 7.73M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4,359.00 |
| Enterprise Value | 7.73M |
Share Statistics
Baudax Bio, Inc. currently has 12.16M shares outstanding.
| Shares Outstanding | 12.16M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 24.95 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Baudax Bio, Inc. maintains a current ratio of 0.07, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.07 |
| Quick Ratio | 0.02 |
| Debt / Equity | -79.09 |
| Debt / EBITDA | -0.37 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -37.57 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.14 |
Stock Price Statistics
Baudax Bio, Inc.'s stock has gained approximately 900% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 900% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Baudax Bio, Inc. generated 310,000.00 in revenue and converted that into -7.15M in net income, yielding earnings per share of -6.48. EBITDA reached -21.70M, while operating income came in at -21.94M.
| Revenue | 310,000.00 |
| Gross Profit | -4.48M |
| Operating Income | -21.94M |
| Pretax Income | -25.83M |
| Net Income | -7.15M |
| EBITDA | -21.70M |
| EBIT | -21.94M |
| Earnings Per Share (EPS) | -6.48 |
Balance Sheet
Baudax Bio, Inc. holds 363,000.00 in cash and equivalents against 8.10M in total debt, resulting in a net debt position of 4.87M. Total book value stands at -189.18M, with working capital of -17.71M providing operational flexibility.
| Cash & Cash Equivalents | 363,000.00 |
| Total Debt | 8.10M |
| Net Debt | 4.87M |
| Equity (Book Value) | -189.18M |
| Book Value Per Share | -47.44 |
| Working Capital | -17.71M |
Cash Flow
Baudax Bio, Inc. produced -14.31M in operating cash flow over the past twelve months.
| Operating Cash Flow | -14.31M |
| Capital Expenditures | N/A |
| Free Cash Flow | -14.31M |
| FCF Per Share | -3.59 |
Margins
Baudax Bio, Inc. operates with a gross margin of -1,445.81, reflecting its pricing power and cost economics. The operating margin of -7,076.45 and net profit margin of -2,308.06 provide insight into operational efficiency.
| Gross Margin | -1,445.81 |
| Operating Margin | -7,076.45 |
| Pretax Margin | -8,331.61 |
| Profit Margin | -2,308.06 |
| EBITDA Margin | -6,999.03 |
Stock Splits
Baudax Bio, Inc.'s most recent stock split took place on December 1, 2022 with a 40:1 split ratio.
| Last Split Date | 12/1/2022 |
| Split Ratio | 40:1 |
Scores
Baudax Bio, Inc. posts an Altman Z-Score of -45.44, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -45.44 |